Clinical Trial
doi: 10.1111/j.1600-0447.1975.tb00220.x.
Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population
- PMID: 235189
- DOI: 10.1111/j.1600-0447.1975.tb00220.x
Item in Clipboard
Clinical Trial
Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population
Acta Psychiatr Scand.
1975 Feb.
Abstract
A study of anti-Parkinsonism agents in prolonged phenothiazine therapy seeks to clarify some anecdotal misconceptions. Antiparkinsonian agents do not appear to affect the therapeutic efficiency of phenothiazines, nor does using them on a "demand" basis increase the problems of control of parkinsonian side effects. Older patients, however, appear to require the extended usage of antiparkinsonian agents rather more than some studies would suggest. Sustained release antiparkinsonian agents may yet further simplify the management of schizophrenia.
Similar articles
-
Tardive dyskinesia treated with pimozide.J Neurol Sci. 1975 Apr;24(4):393-401. doi: 10.1016/0022-510x(75)90165-3. J Neurol Sci. 1975. PMID: 235013 Clinical Trial.
-
Drug-induced dystonia.Am J Psychiatry. 1975 May;132(5):532-4. doi: 10.1176/ajp.132.5.532. Am J Psychiatry. 1975. PMID: 1119613
-
Effects of antipsychotic drugs on memory functions of schizophrenic patients.Acta Psychiatr Scand. 1992 Jan;85(1):74-6. doi: 10.1111/j.1600-0447.1992.tb01446.x. Acta Psychiatr Scand. 1992. PMID: 1347670 Clinical Trial.
-
Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald.Psychol Bull. 1976 May;83(3):431-47. Psychol Bull. 1976. PMID: 6986 Review. No abstract available.
-
Maintenance therapy and schizophrenia.Br J Psychiatry. 1975;Spec No 9:55-8. Br J Psychiatry. 1975. PMID: 241453 Review. No abstract available.
Cited by
-
Haloperidol versus chlorpromazine for schizophrenia.Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD004278. doi: 10.1002/14651858.CD004278.pub2. Cochrane Database Syst Rev. 2008. PMID: 18254045 Free PMC article.
-
Fluphenazine (oral) versus placebo for schizophrenia.Cochrane Database Syst Rev. 2013 Jul 17;7(7):CD006352. doi: 10.1002/14651858.CD006352.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2018 Jun 12;6:CD006352. doi: 10.1002/14651858.CD006352.pub3. PMID: 23861067 Free PMC article. Updated.
-
Fluphenazine (oral) versus placebo for schizophrenia.Cochrane Database Syst Rev. 2018 Jun 12;6(6):CD006352. doi: 10.1002/14651858.CD006352.pub3. Cochrane Database Syst Rev. 2018. PMID: 29893410 Free PMC article.
-
Melanocytotoxic chemicals and their toxic mechanisms.Toxicol Res. 2022 Aug 22;38(4):417-435. doi: 10.1007/s43188-022-00144-2. eCollection 2022 Oct. Toxicol Res. 2022. PMID: 36277364 Free PMC article. Review.
-
Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease.Int J Mol Sci. 2012;13(8):10608-10629. doi: 10.3390/ijms130810608. Epub 2012 Aug 23. Int J Mol Sci. 2012. PMID: 22949883 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
